Here's what's behind their impressive market performances.
News & Analysis: Stemline Therpeutics
The ultimate binary event caused the biotech's shares to jump.
STML earnings call for the period ending December 31, 2019.
The launch of blood cancer drug Elzonris is slowing.
STML earnings call for the period ending October 30, 2019.
STML earnings call for the period ending June 30, 2019.
STML earnings call for the period ending March 31, 2019.
Impressive pivotal trial results suggest an application for the company's troubled candidate is headed to the FDA.
Stemline's lead drug dazzles in a pivotal-stage study, but investors should temper their expectations for the time being.
The clinical-stage oncology company is facing the same hurdles as better-known peers when it comes to next-generation immunotherapy development.